Skip to content

Study · Randomized controlled trial · n = 100 · 1999

7 results

Randomized controlled trial of depot leuprolide in patients with chronic pelvic pain and clinically suspected endometriosis. Pelvic Pain Study Group.

Ling FW

Obstetrics and gynecology1 Jan 1999Cited by 131 (Europe PMC)

PMID9916956 (opens in a new tab)DOI10.1016/s0029-7844(98)00341-x (opens in a new tab)PepBankPUB-09916956
Publisher pagePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

  1. 01HumanRandomized controlled trialSafety outcome

    In women with suspected endometriosis, no participants withdrew because of adverse events with leuprolide or placebo.

    In plain wordsIn women with suspected endometriosis, no participants stopped leuprolide or placebo because of adverse events.

    Peptide
    Leuprolide
    Outcome
    Not applicableWithdrawal because of adverse events
    Study

    n = 100

    Comparator
    Placebo
    Outcome group
    Adverse events · Reproductive and sexual health
    Studied dose
    3.75 mg/mo · 3 monthsAs given in this study (human).

    Source sentences

    Summary
    No women withdrew from the study because of adverse events.
    1 context sentence
    Summary · context
    Those with clinically suspected endometriosis were randomized to double-blind treatment for 3 months with depot leuprolide (3.75 mg/mo) or placebo.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In women with suspected endometriosis, leuprolide improved pain measures more than placebo (P < or = .001).

    In plain wordsIn women with suspected endometriosis, leuprolide improved pain measures more than placebo.

    Peptide
    Leuprolide
    Outcome
    Direction not reportedPain improvement versus placebo
    Study

    n = 95

    Comparator
    Placebo
    Outcome group
    Pain · Reproductive and sexual health
    Studied dose
    3.75 mg/mo · 3 monthsAs given in this study (human).

    Source sentences

    Summary
    These mean improvements were significantly greater (P < or = .001) than those in the placebo group.
    2 context sentences
    Summary · context
    Women in the leuprolide group had clinically and statistically significant (P < or = .001) mean improvements from baseline after 12 weeks of therapy in all pain measures.
    Summary · context
    Those with clinically suspected endometriosis were randomized to double-blind treatment for 3 months with depot leuprolide (3.75 mg/mo) or placebo.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In women with suspected endometriosis, physician-rated dysmenorrhea scores decreased 1.7 points more with leuprolide than placebo on a four-point scale at 12 weeks.

    In plain wordsIn women with suspected endometriosis, leuprolide reduced menstrual pain scores more than placebo.

    Peptide
    Leuprolide
    Outcome
    DecreaseDysmenorrhea score
    Study

    n = 95

    Comparator
    Placebo
    Outcome group
    Pain · Reproductive and sexual health
    Studied dose
    3.75 mg/mo · 3 monthsAs given in this study (human).

    Measurements

    Between-group difference in mean decrease, dysmenorrhea score
    1.7 points
    leuprolide minus placebo, 12 weeks, four-point physician-rated scale

    Source sentences

    Summary
    At 12 weeks, mean decreases in physician-rated scores for dysmenorrhea, pelvic pain, and pelvic tenderness were 1.7, 1.0, and 0.8 points greater, respectively, in the leuprolide group than in the placebo group (on a four-point scale).
    1 context sentence
    Summary · context
    Those with clinically suspected endometriosis were randomized to double-blind treatment for 3 months with depot leuprolide (3.75 mg/mo) or placebo.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In women with suspected endometriosis, physician-rated pelvic pain scores decreased 1.0 points more with leuprolide than placebo on a four-point scale at 12 weeks.

    In plain wordsIn women with suspected endometriosis, leuprolide reduced pelvic pain scores more than placebo.

    Peptide
    Leuprolide
    Outcome
    DecreasePelvic pain score
    Study

    n = 95

    Comparator
    Placebo
    Outcome group
    Pain · Reproductive and sexual health
    Studied dose
    3.75 mg/mo · 3 monthsAs given in this study (human).

    Measurements

    Between-group difference in mean decrease, pelvic pain score
    1 points
    leuprolide minus placebo, 12 weeks, four-point physician-rated scale

    Source sentences

    Summary
    At 12 weeks, mean decreases in physician-rated scores for dysmenorrhea, pelvic pain, and pelvic tenderness were 1.7, 1.0, and 0.8 points greater, respectively, in the leuprolide group than in the placebo group (on a four-point scale).
    1 context sentence
    Summary · context
    Those with clinically suspected endometriosis were randomized to double-blind treatment for 3 months with depot leuprolide (3.75 mg/mo) or placebo.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In women with suspected endometriosis, physician-rated pelvic tenderness scores decreased 0.8 points more with leuprolide than placebo on a four-point scale at 12 weeks.

    In plain wordsIn women with suspected endometriosis, leuprolide reduced pelvic tenderness scores more than placebo.

    Peptide
    Leuprolide
    Outcome
    DecreasePelvic tenderness score
    Study

    n = 95

    Comparator
    Placebo
    Outcome group
    Pain · Reproductive and sexual health
    Studied dose
    3.75 mg/mo · 3 monthsAs given in this study (human).

    Measurements

    Between-group difference in mean decrease, pelvic tenderness score
    0.8 points
    leuprolide minus placebo, 12 weeks, four-point physician-rated scale

    Source sentences

    Summary
    At 12 weeks, mean decreases in physician-rated scores for dysmenorrhea, pelvic pain, and pelvic tenderness were 1.7, 1.0, and 0.8 points greater, respectively, in the leuprolide group than in the placebo group (on a four-point scale).
    1 context sentence
    Summary · context
    Those with clinically suspected endometriosis were randomized to double-blind treatment for 3 months with depot leuprolide (3.75 mg/mo) or placebo.
  6. 06HumanRandomized controlled trialEfficacy outcome

    After treatment, endometriosis was confirmed in 38 (78%) of 49 leuprolide recipients versus 40 (87%) of 46 placebo recipients.

    In plain wordsEndometriosis was confirmed after treatment in 78% of leuprolide recipients and 87% of placebo recipients.

    Peptide
    Leuprolide
    Outcome
    DecreaseLaparoscopic endometriosis confirmation
    Study

    n = 95

    Comparator
    Placebo
    Outcome group
    Diagnostic confirmation · Reproductive and sexual health
    Studied dose
    3.75 mg/mo · 3 monthsAs given in this study (human).

    Measurements

    Laparoscopically confirmed endometriosis
    38 patients
    leuprolide, of 49
    Laparoscopically confirmed endometriosis
    78%
    leuprolide
    Laparoscopically confirmed endometriosis
    40 patients
    placebo, of 46
    Laparoscopically confirmed endometriosis
    87%
    placebo

    Source sentences

    Summary
    Thirty-eight (78%) of 49 and 40 (87%) of 46 patients in the leuprolide and placebo groups, respectively, had laparoscopically confirmed endometriosis after 12 weeks of treatment.
    1 context sentence
    Summary · context
    Those with clinically suspected endometriosis were randomized to double-blind treatment for 3 months with depot leuprolide (3.75 mg/mo) or placebo.
  7. 07HumanNon-randomized trialEfficacy outcome

    In women with suspected endometriosis, leuprolide improved all pain measures from baseline after 12 weeks (P < or = .001).

    In plain wordsIn women with suspected endometriosis, all pain measures improved from baseline after leuprolide treatment.

    Peptide
    Leuprolide
    Outcome
    Direction not reportedPain measures from baseline
    Study

    n = 49

    Comparator
    Baseline
    Outcome group
    Pain · Reproductive and sexual health
    Studied dose
    3.75 mg/mo · 3 monthsAs given in this study (human).

    Source sentences

    Summary
    Women in the leuprolide group had clinically and statistically significant (P < or = .001) mean improvements from baseline after 12 weeks of therapy in all pain measures.
    1 context sentence
    Summary · context
    Those with clinically suspected endometriosis were randomized to double-blind treatment for 3 months with depot leuprolide (3.75 mg/mo) or placebo.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:37 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.